Gervais Bérubé

The design of innovative compounds displaying anti-inflammatory activity in oncological context is a subject of great interest in drug development. It has been proved that a pro-inflammatory microenvironment which accelerates cancer growth and cellular differentiation is often present in malignant bladder tumor. In earlier work, we reported the synthesis of p-aminobenzoic acid derivatives that act as anti-inflammatory compounds able to inhibit the pro-inflammatory markers present in bladder cancer microenvironment. DAB-1 rapidly emerged as an effective lead candidate in this investigation, with its ability to shrink by 90% in 25 days the size of human bladder cancer tumors in an ectopic mouse model. This manuscript discloses the synthesis of 23 new hydrazide derivatives of DAB-1 and reports their in vitro and in vivo biological evaluation. It was discovered that most of the new compounds are essentially nontoxic against RAW 264.7 cells, as evaluated by an MTT assay. Anti-inflammatory activity of the new derivatives was investigated by evaluation of their impact on cellular nitric oxide production, measured by a Griess assay. Some compounds did significatively inhibit nitric oxide production much more effectively than the original DAB-1. Striking activity of 14, which is around four times more potent than DAB-1, promotes this derivative as new lead compound in this study. The study of these analogs reveals that a phenolic/anisole core is a key component to achieve high biological activity. Furthermore, mice models of acute inflammation and invasive BCa tumors were used to assess the in vivo impact of derivative 14, and it was found that this compound does reduce inflammation in these mice, possess similar anti-inflammatory activity but higher anti-tumoral activity compared to DAB-1 with no apparent signs of toxicity.

Macrophage-mediated inflammation is known to be involved in the epithelial–mesenchymal transition (EMT) of various types of cancer. This makes macrophage-derived inflammatory factors prime targets for the development of new treatments. This study uncovers the therapeutic potential and action mechanism of DAB-2-28, a small-molecule derived from para-aminobenzoic acid, in the treatment of breast cancer. The luminal MCF-7 and the triple-negative MDA-MB-231 cancer cell lines used in this study represent, respectively, breast cancers in which the differentiation states are related to the epithelial phenotype of the mammary gland and breast cancers expressing a highly aggressive mesenchymal phenotype. In MCF-7 cells, soluble factors from macrophage-conditioned media (CM-MØ) induce a characteristic morphology of mesenchymal cells with an upregulated expression of Snail1, a mesenchymal marker, as opposed to a decrease in the expression of E-cadherin, an epithelial marker. DAB-2-28 does not affect the differential expression of Snail1 and E-cadherin in response to CM-MØ, but negatively impacts other hallmarks of EMT by decreasing invasion and migration capacities, in addition to MMP9 expression and gelatinase activity, in both MCF-7 and MDA-MB-231 cells. Moreover, DAB-2-28 inhibits the phosphorylation of key pro-EMT transcriptional factors, such as NFκB, STAT3, SMAD2, CREB, and/or AKT proteins, in breast cancer cells exposed to different EMT inducers. Overall, our study provides evidence suggesting that inhibition of EMT initiation or maintenance is a key mechanism by which DAB-2-28 can exert anti-tumoral effects in breast cancer cells.

Macrophage-mediated inflammation is proposed to be involved in the epithelial-mesenchymal transition (EMT) of different types of cancers. This makes macrophage-derived inflammatory factors a prime target for developing new treatments. This study aims to demonstrate the therapeutic potential and mechanism of action of DAB-2-28, a novel small molecule derived from aminobenzoic acid, in the treatment of breast cancer. The luminal MCF-7 and the triple-negative MDA-MB-231 cancer cell lines used in this study represent, respectively, a breast cancer whose differentiation state is related to the epithelial phenotype of the mammary gland, and a breast cancer expressing a highly aggressive mesenchymal phenotype. In MCF-7 cells, soluble factors from macrophage-conditioned media (MØ-CM) induce a characteristic morphology of mesenchymal cells with an increase in the expression of Snail1, a mesenchymal marker, opposed to a decrease in the expression of E-cadherin, an epithelial marker. Although our studies demonstrated that DAB-2-28 does not affect the differential expression of Snail1 and E-cadherin, DAB-2-28 negatively regulates the different responses of MCF-7 cells to MØ-CM by decreasing a) clonogenic growth; b) invasion and migration capacities; c) MMP9 expression and gelatinase activity; and d) NFkB, STAT3, AKT, and SMAD2 protein phosphorylation. Moreover, differential expression of Snail1 and E-cadherin in MCF-7 cells was also induced by the cytokines TNFa and TGFb1, alone or in combination, and the StemXvivo® EMT Inducing Media reagent. DAB-2-28 affects the response of MCF-7 cells to these various EMT inducers by inhibiting the phosphorylation of NFkB, SMAD2 and/or CREB proteins. Finally, DAB-2-28 also decreases the macrophage- and cytokine-induced invasion and migration capacities of MDA-MB-231 cells, probably via an inhibition of MMP9 activity and the phosphorylation of NFkB, STAT3, AKT, SMAD2, and CREB proteins. We propose that the ability of DAB-2-28 to prevent cancer cells from acquiring EMT-related protumor properties could be exploited in a clinical setting to block disease progression to a metastatic form and thus improve the survival rate of breast cancer patients.

The conjugation of chitosan 15 and 100 KD with anticancer drugs cis– and trans–Pt (NH₃)₂Cl₂ (abbreviated cis–Pt and trans–Pt) were studied at pH 5–6. Using multiple spectroscopic methods and thermodynamic analysis to characterize the nature of drug–chitosan interactions and the potential application of chitosan nanoparticles in drug delivery. Analysis showed that both hydrophobic and hydrophilic contacts are involved in drug–polymer interactions, while chitosan size and charge play a major role in the stability of drug–polymer complexes. The overall binding constants are K_{ch–15–cis–Pt} = 1.44 (±0.6) × 10⁵ M⁻¹, K_{ch–100–cis–Pt} = 1.89 (±0.9) × 10⁵ M⁻¹ and K_{ch–15–trans–Pt} = 9.84 (±0.5) × 10⁴ M⁻¹, and K_{ch–100–trans–Pt} = 1.15 (±0.6) × 10⁵ M⁻¹. More stable complexes were formed with cis–Pt than with trans–Pt–chitosan adducts, while stronger binding was observed for chitosan 100 in comparison to chitosan 15 KD. This study indicates that polymer chitosan 100 is a stronger drug carrier than chitosan 15 KD in vitro.

Amaryllidaceae alkaloids (AAs) are a structurally diverse family of alkaloids recognized for their many therapeutic properties, such as antiviral, anti-cholinesterase, and anticancer properties. Norbelladine and its derivatives, whose biological properties are poorly studied, are key intermediates required for the biosynthesis of all ~650 reported AAs. To gain insight into their therapeutic potential, we synthesized a series of O-methylated norbelladine-type alkaloids and evaluated their cytotoxic effects on two types of cancer cell lines, their antiviral effects against the dengue virus (DENV) and the human immunodeficiency virus 1 (HIV-1), and their anti-Alzheimer’s disease (anti-cholinesterase and -prolyl oligopeptidase) properties. In monocytic leukemia cells, norcraugsodine was highly cytotoxic (CC₅₀ = 27.0 μM), while norbelladine was the most cytotoxic to hepatocarcinoma cells (CC₅₀ = 72.6 μM). HIV-1 infection was impaired only at cytotoxic concentrations of the compounds. The 3,4-dihydroxybenzaldehyde (selectivity index (SI) = 7.2), 3′,4′-O-dimethylnorbelladine (SI = 4.8), 4′-O-methylnorbelladine (SI > 4.9), 3′-O-methylnorbelladine (SI > 4.5), and norcraugsodine (SI = 3.2) reduced the number of DENV-infected cells with EC₅₀ values ranging from 24.1 to 44.9 μM. The O-methylation of norcraugsodine abolished its anti-DENV potential. Norbelladine and its O-methylated forms also displayed butyrylcholinesterase-inhibition properties (IC₅₀ values ranging from 26.1 to 91.6 μM). Altogether, the results provided hints of the structure–activity relationship of norbelladine-type alkaloids, which is important knowledge for the development of new inhibitors of DENV and butyrylcholinesterase.